RHEUMATOLOGY · RHEUMATOID ARTHRITIS
Baricitinib Rheumatoid Arthritis Safety Study
A Phase 3b/4 study comparing selected safety outcomes for baricitinib and TNF-inhibitor treatment.
Study overview
This randomized, active-controlled Phase 3b/4 study evaluates baricitinib in adults with rheumatoid arthritis and compares selected safety outcomes with tumor necrosis factor inhibitor treatment. The study was designed to examine venous thromboembolic events and other protocol-defined outcomes in a population for whom these treatments may be considered. Treatment assignment, dose, background medicines, and follow-up are controlled by the research protocol and qualified study clinicians.
What researchers are evaluating
Researchers may monitor blood clots, cardiovascular events, infections, laboratory changes, rheumatoid arthritis activity, medication exposure, and other adverse events. Assessments can include medical-history and medication reviews, physical examinations, blood tests, pregnancy testing when applicable, and evaluation of symptoms that may require urgent attention. Baricitinib and TNF inhibitors have established prescribing information, warnings, and contraindications, but participation in a comparative safety study has additional protocol requirements. This page does not recommend a drug or compare which treatment is appropriate for an individual.
Considering participation
Potential eligibility may depend on age, rheumatoid arthritis history and activity, previous disease-modifying treatment, current medicines, cardiovascular or blood-clot risk factors, infections, vaccination status, laboratory results, pregnancy-related requirements, and other health conditions. The official protocol and clinical review determine eligibility. Study status and local availability may change; a listed study is not necessarily recruiting. Participation is voluntary, and informed consent explains assignment, visits, procedures, foreseeable risks, possible benefits, alternatives, confidentiality, and withdrawal rights. Patients should continue to seek treatment advice from their own qualified clinician. Do not include medical records, medication lists, insurance information, or other sensitive details in the initial inquiry.